Washington—Clinicians need to brace themselves for another round in the protracted debate over the value of routine prostate-specific antigen (PSA) screening. A new study from Stanford University School of Medicine contends that PSA scores between 2 ng/mL and 9 ng/mL are "clinically useless" in predicting the size and aggressiveness of prostate tumors. The group, led by Thomas Stamey, MD, also concludes that PSA values in that middle range "have a limited relationship with [surgical] cure rates" (J Urology. 2002;167:103-111).
Vastag B. Study Concludes That Moderate PSA Levels Are Unrelated to Prostate Cancer Outcomes. JAMA. 2002;287(8):969–970. doi:10.1001/jama.287.8.969
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: